EBCC 2024 | Impact of the SINODAR-ONE trial on clinical practice

Ruggero Spoto, MD, Humanitas Research Hospital, Milan, Italy, outlines the impacts of the SINODAR-ONE trial (NCT05160324) on clinical practice for breast cancer treatment. The SINODAR-ONE trial suggests that it is safe to omit surgery or radiotherapy of the axillary node in patients undergoing breast surgery, reducing morbidity and comorbidity of breast cancer treatment. This interview took place at the 14th European Breast Cancer Conference (EBCC) in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.